Format

Send to

Choose Destination
J Immunol Res. 2017;2017:6804678. doi: 10.1155/2017/6804678. Epub 2017 Jan 3.

Desensitization: Overcoming the Immunologic Barriers to Transplantation.

Author information

1
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Abstract

HLA (Human Leucocyte Antigen) sensitization is a significant barrier to successful kidney transplantation. It often translates into difficult crossmatch before transplant and increased risk of acute and chronic antibody mediated rejection after transplant. Over the last decade, several immunomodulatory therapies have emerged allowing for increased access to kidney transplantation for the immunologically disadvantaged group of HLA sensitized end stage kidney disease patients. These include IgG inactivating agents, anti-cytokine antibodies, costimulatory molecule blockers, complement inhibitors, and agents targeting plasma cells. In this review, we discuss currently available agents for desensitization and provide a brief analysis of data on novel biologics, which will likely improve desensitization outcomes, and have potential implications in treatment of antibody mediated rejection.

PMID:
28127571
PMCID:
PMC5239985
DOI:
10.1155/2017/6804678
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center